ConductScience.org, home

Paper41597491

Early SGLT2 Inhibitor Therapy in Acute Coronary Syndrome: Mitigating Adverse Remodeling in High-Risk Phenotypes-A Real-World Study.

Mateoc T and 8 others. Medicina (Kaunas), 2026. Cited by 2 papers, by iCite.

Cite this record

ConductScience Library. Early SGLT2 Inhibitor Therapy in Acute Coronary Syndrome: Mitigating Adverse Remodeling in High-Risk Phenotypes-A Real-World Study. Papers, record 41597491. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41597491

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Early SGLT2 Inhibitor Therapy in Acute Coronary Syndrome: Mitigating Adverse Remodeling in High-Risk Phenotypes-A Real-World Study.
PubMed
Journal
Medicina (Kaunas)
PubMed
Year
2026
PubMed
Publication types
Journal Article, Observational Study
PubMed
Citations, by iCite
2
iCite
Revised in PubMed
2026-01-31
PubMed

Authors9

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Mateoc TTeodorahttps://orcid.org/0009-0007-0723-2735
2Suciu IMIoana-Maria
3Gaiță DDanhttps://orcid.org/0000-0003-0320-6779
4Minodora AAndor
5Popescu RRoxanahttps://orcid.org/0000-0002-9387-1141
6Vlad TTania
7Flangea CCorina
8Muntean CCălinhttps://orcid.org/0000-0002-0497-0405
9Vlad DCDaliborca-Cristinahttps://orcid.org/0000-0002-9243-1865

Source PubMed

Download CSV of authors

Topics11

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Acute Coronary SyndromeMajor topic
Sodium-Glucose Transporter 2 InhibitorsMajor topic
Ventricular RemodelingMajor topic
Humans
Male
Female
Retrospective Studies
Middle Aged
Aged
Phenotype
Echocardiography

Source PubMed

Download CSV of topics

References49

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
137056987Post-myocardial infarction fibrosis: Pathophysiology, examination, and intervention.Front Pharmacol2023https://conductscience.org/library/papers/37056987PubMed
241303447Left Ventricular Remodeling After Myocardial Infarction-Pathophysiology, Diagnostic Approach and Management During Cardiac Rehabilitation.Int J Mol Sci2025https://conductscience.org/library/papers/41303447PubMed
334767896Prognostic relevance of peri-infarct zone measured by cardiovascular magnetic resonance in patients with ST-segment elevation myocardial infarction.Int J Cardiol2022https://conductscience.org/library/papers/34767896PubMed
435595091Empagliflozin in patients post myocardial infarction rationale and design of the EMPACT-MI trial.Am Heart J2022https://conductscience.org/library/papers/35595091PubMed
530132036SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review.Diabetologia2018https://conductscience.org/library/papers/30132036PubMed
635892913Left Ventricular Remodeling after Myocardial Infarction: From Physiopathology to Treatment.Life (Basel)2022https://conductscience.org/library/papers/35892913PubMed
718313558The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies.J Clin Epidemiol2008https://conductscience.org/library/papers/18313558PubMed
831535829Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction.N Engl J Med2019https://conductscience.org/library/papers/31535829PubMed
938320489Dapagliflozin in Myocardial Infarction without Diabetes or Heart Failure.NEJM Evid2024https://conductscience.org/library/papers/38320489PubMed
1030206484Metabolic Modulation of Cardiac Metabolism in Heart Failure.Card Fail Rev2018https://conductscience.org/library/papers/30206484PubMed
1112361819Heart failure after myocardial infarction: a review.Am J Med2002https://conductscience.org/library/papers/12361819PubMed
1240702419A predictive model for heart failure with preserved ejection fraction following acute myocardial infarction: the HFpEF-AMI score.BMC Cardiovasc Disord2025https://conductscience.org/library/papers/40702419PubMed
1337087452The global prevalence of myocardial infarction: a systematic review and meta-analysis.BMC Cardiovasc Disord2023https://conductscience.org/library/papers/37087452PubMed
1441121256Emerging therapy strategies for energy metabolism in acute myocardial infarction.J Transl Med2025https://conductscience.org/library/papers/41121256PubMed
1517934906Alterations in energy metabolism in cardiomyopathies.Ann Med2007https://conductscience.org/library/papers/17934906PubMed
1621264498Temporal relation of cardiac hypertrophy, oxidative stress, and fatty acid metabolism in spontaneously hypertensive rat.Mol Cell Biochem2011https://conductscience.org/library/papers/21264498PubMed
1710869273Left ventricular remodeling after myocardial infarction: pathophysiology and therapy.Circulation2000https://conductscience.org/library/papers/10869273PubMed
1840972782Impact of empagliflozin and dapagliflozin on sudden cardiac death: A systematic review and meta-analysis of adjudicated randomized evidence.Heart Rhythm2026https://conductscience.org/library/papers/40972782PubMed
1936615133Left Ventricular Adverse Remodeling in Ischemic Heart Disease: Emerging Cardiac Magnetic Resonance Imaging Biomarkers.J Clin Med2023https://conductscience.org/library/papers/36615133PubMed
2041253261Mechanistic insights and clinical horizons of SGLT2 inhibitors in heart failure management.Trends Cardiovasc Med2026https://conductscience.org/library/papers/41253261PubMed

See all 49 referencesDownload CSV of references

Cited by1

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 2 citations.

PMIDTitleJournalYearIn Papers
41682737Patterns in Prescribing and Predictors of SGLT2 Inhibitor Administration in Patients with Heart Failure and Acute Myocardial Infarction: A Real-World Retrospective Cohort Study.J Clin Med2026https://conductscience.org/library/papers/41682737

Source PubMed

Download CSV of cited by

Genes1

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn Genes
SLC5A26524PubTator's text mininghttps://conductscience.org/library/genes/6524

Source NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/41597491

GET https://conductscience.org/api/papers/v1/41597491/references?page=2